# Premier Air Charter Holdings Inc.: overview PREM · OTC · CIK 1570937 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/prem.md) · [Financials](/companies/prem/financials.md) · [Filings](/companies/prem/filings.md) · [Insiders](/companies/prem/insiders.md) Latest reported revenue: [$5.8m](/filings/0001683168-26-006482.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001683168-26-006482). ## Last eight quarters | Line item | Unit | Q2 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.0](/filings/0001683168-25-008436.md) | [5.5 d](/filings/0001683168-26-003005.md) | [5.9](/filings/0001683168-26-004025.md) | [7.4](/filings/0001683168-26-006482.md) | [7.1](/filings/0001683168-25-008436.md) | [11.5 d](/filings/0001683168-26-003005.md) | [7.2](/filings/0001683168-26-004025.md) | [5.8](/filings/0001683168-26-006482.md) | | Gross margin | % | [(3.8%)](/filings/0001683168-25-008436.md) | [20.8% d](/filings/0001683168-26-003005.md) | [2.5%](/filings/0001683168-26-004025.md) | [3.0%](/filings/0001683168-26-006482.md) | [(6.3%)](/filings/0001683168-25-008436.md) | [30.2% d](/filings/0001683168-26-003005.md) | [7.5%](/filings/0001683168-26-004025.md) | [(0.6%)](/filings/0001683168-26-006482.md) | | Operating margin | % | [(23.0%)](/filings/0001683168-25-008436.md) | [(0.5%) d](/filings/0001554795-25-000032.md) | [(14.6%)](/filings/0001683168-26-004025.md) | [(11.1%)](/filings/0001683168-26-006482.md) | [(21.0%)](/filings/0001683168-25-008436.md) | [4.1% d](/filings/0001683168-26-003005.md) | [(10.3%)](/filings/0001683168-26-004025.md) | [(15.7%)](/filings/0001683168-26-006482.md) | | Net margin | % | [(29.4%)](/filings/0001683168-25-008436.md) | [(0.6%) d](/filings/0001554795-25-000032.md) | [(20.8%)](/filings/0001683168-26-006482.md) | [(13.5%)](/filings/0001683168-26-006482.md) | [(25.5%)](/filings/0001683168-25-008436.md) | [1.4% d](/filings/0001683168-26-003005.md) | [(16.1%)](/filings/0001683168-26-006482.md) | [(22.3%)](/filings/0001683168-26-006482.md) | | Diluted EPS | $ per share | [0.00](/filings/0001683168-25-008436.md) | not reported | [0.00](/filings/0001683168-26-004025.md) | [0.00](/filings/0001683168-26-006482.md) | [(0.01)](/filings/0001683168-25-008436.md) | not reported | [0.00](/filings/0001683168-26-004025.md) | [0.00](/filings/0001683168-26-006482.md) | | Free cash flow | $m | [0.6 d](/filings/0001683168-25-008436.md) | [0.6 d](/filings/0001683168-26-003005.md) | [0.3](/filings/0001683168-26-004025.md) | [0.5 d](/filings/0001683168-26-006482.md) | [(2.4) d](/filings/0001683168-25-008436.md) | [0.2 d](/filings/0001683168-26-003005.md) | [0.5](/filings/0001683168-26-004025.md) | [(0.2) d](/filings/0001683168-26-006482.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2023 (2023-03-31) | FY2023 (2023-12-31) | FY2024 (2024-03-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [20.2](/filings/0001683168-25-002316.md) | not reported | [20.8](/filings/0001683168-26-003005.md) | [31.9](/filings/0001683168-26-003005.md) | | Gross margin | % | not reported | [15.6%](/filings/0001683168-25-002316.md) | not reported | [11.5%](/filings/0001683168-26-003005.md) | [10.6%](/filings/0001683168-26-003005.md) | | Operating margin | % | not reported | [(1.3%)](/filings/0001683168-25-002316.md) | not reported | [(5.5%)](/filings/0001683168-26-003005.md) | [(8.5%)](/filings/0001683168-26-003005.md) | | Net margin | % | not reported | [(0.7%)](/filings/0001683168-25-002316.md) | not reported | [(10.6%)](/filings/0001683168-26-003005.md) | [(12.1%)](/filings/0001683168-26-003005.md) | | Diluted EPS | $ per share | not reported | [0.00](/filings/0001683168-25-002316.md) | not reported | [(0.01)](/filings/0001683168-26-003005.md) | [(0.01)](/filings/0001683168-26-003005.md) | | Free cash flow | $m | not reported | [0.2](/filings/0001683168-25-002316.md) | not reported | [1.6](/filings/0001683168-26-003005.md) | [(1.4)](/filings/0001683168-26-003005.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/prem/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FIRST AMERICAN TRUST, FSB](/funds/36066.md) | 2026-06-30 | $2.7k | 49,751 | | Unchanged | ## Recent filings [All 207 filings](/companies/prem/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 17:04 ET | [8-K](/filings/0001683168-26-008054.md) | 5.02 Departure or appointment of officers or directors | 0001683168-26-008054 | | 2026-10-13 | 21:25 ET | [8-K](/filings/0001683168-26-007816.md) | 1.02 Termination of a material agreement; 2.04 Item not in the standard list; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors | 0001683168-26-007816 | | 2026-08-14 | 20:29 ET | [10-Q](/filings/0001683168-26-006482.md) | Quarterly report, period 2026-06-30 | 0001683168-26-006482 | | 2026-06-26 | 21:00 ET | [8-K](/filings/0001683168-26-005138.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001683168-26-005138 | | 2026-05-15 | 19:38 ET | [10-Q](/filings/0001683168-26-004025.md) | Quarterly report, period 2026-03-31 | 0001683168-26-004025 | | 2026-04-28 | 20:38 ET | [8-K](/filings/0001683168-26-003272.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001683168-26-003272 | | 2026-04-15 | 21:26 ET | [10-K](/filings/0001683168-26-003005.md) | Annual report, period 2025-12-31 | 0001683168-26-003005 | | 2026-02-25 | 22:00 ET | [8-K](/filings/0001683168-26-001301.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001683168-26-001301 | | 2025-11-14 | 20:22 ET | [10-Q](/filings/0001683168-25-008436.md) | Quarterly report, period 2025-09-30 | 0001683168-25-008436 | | 2025-11-13 | 21:06 ET | [8-K](/filings/0001683168-25-008327.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001683168-25-008327 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001683168-26-003005.md), filed Apr 15, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c50130e9-fd68-4af8-bf0a-05fc8de3ce0c) ## About the filer - CIK: 1570937 - Tickers: PREM - Exchange: OTC - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.